EMA to review Shire application for blood disorder therapy

The European Medicines Agency has agreed to review London-listed Shire’s (LSE: SHP) application for approval to market Veyvondi (von Willebrand factor) as a treatment for von Willebrand Disease (VWD), the most common inherited bleeding disorder.

The therapy was approved in the USA in December 2015, where it is marketed as Vonvendi.

VWD is the most common inherited bleeding disorder worldwide, affecting up to 1% of the world’s population. It is caused by a deficiency or dysfunction of von Willebrand factor, resulting in impaired blood clotting.